



Published on NAVADHI Market Research (<https://www.navadhi.com>)

[Home](#) > GlaxoSmithKline Plc - Company Snapshot & SWOT Analysis

GlaxoSmithKline Plc - Company Snapshot & SWOT Analysis



Publication ID:

NAV0319009

Publication Date:

March 06, 2019

Pages:

30

Countries:

[Global](#) [1]

Publication License Type *

Single User License (PDF), \$350.00

Enterprise License (PDF), \$500.00

Please choose the suitable license type from above. More details are at given under tab "Report License Types" below.

Add to cart

Add to wish list



As per NAVADHI Market Research, the [global pharmaceutical industry](#) [2] will be worth **USD 1.57 trillion** by 2023.


GlaxoSmithKline (GSK) is a global pharmaceutical and consumer health products company and is headquartered in Brentford, the UK. The company operates in more than 100 countries and has a strong presence in US, Europe and Asia-Pacific.

GLAXOSMITHKLINE PLC 2018 PERFORMANCE AT A GLANCE


COMPANY SALES, EBITDA & EPS



SALES BY BUSINESS UNIT



TOP SELLING GEOGRAPHY



R&D HIGHLIGHTS

2018 \$ *5.17 Billion

TOP SELLING DRUG



*Only Pharma R&D Spending



Graphics are solely for presentation purpose only, for more detail please refer to actual market research report

GSK is looking forward to expanding its product portfolio and is investing heavily on Research and development for the same. The company has 3 global businesses that research, develop and manufacture innovative pharmaceutical medicines, vaccines and consumer healthcare products.

GlaxoSmithKline reported revenue of USD 40.992 billion for the FY 2018 which saw an increase of 4.46% compared to FY 2017. Consumer healthcare division had second largest revenue share with 24.85% revenue share. This division saw an increase of 1.09% compared to FY 2017 revenue.

GlaxoSmithKline registered highest revenue from respiratory (Seretide/ Advair, Ellipta Products (Anoro Ellipta, Arnuity Ellipta, Incruse Ellipta, Relvar/ Breo Ellipta, Trelegly Ellipta), Nucala/ Mepolizumab, Avamys/ Veramyst, Flixotide/ Flovent, Ventolin and Other) at USD 9.214 billion which accounted for 40.12% of its total pharmaceuticals sales in FY 2018.

Spanning over 29 pages and 10 exhibits, "GlaxoSmithKline Plc - Company Snapshot & SWOT Analysis" report provides value chain analysis, financial performance, business strategy and SWOT analysis for company.

Scope of the GlaxoSmithKline Plc- Company Snapshot & SWOT Analysis Report

- This report provides detailed information about GlaxoSmithKline Plc including value chain analysis, financial performance, business strategy and SWOT analysis.
- The report identifies the growth drivers and inhibitors for global pharmaceutical market.
- This report provides information about current and future trends for global pharmaceutical market.

1. Executive Summary

Scope of the GlaxoSmithKline Plc- Company Snapshot & SWOT Analysis Report
Research Methodology

2. Growth Drivers and Inhibitors for Global Pharmaceuticals Market

3. Company Profile

3.1 GlaxoSmithKline Plc

3.1.1. Company Profile

3.1.2 GlaxoSmithKline Plc in Global Pharmaceuticals Manufacturing Value Chain

3.1.3 GlaxoSmithKline Plc: Financial Performance

3.1.3.1 GlaxoSmithKline Plc: Overall Revenue FY 2013-FY 2019 (in USD billion)

3.1.3.2 GlaxoSmithKline Plc: Division-Wise Revenue FY 2018 (in USD billion)

3.1.3.3 GlaxoSmithKline Plc: Geography-Wise Revenue FY 2018 (in USD billion)

3.1.3.4 GlaxoSmithKline Plc: Therapy Area-Wise Revenue FY 2018 (in USD billion)

3.1.4 GlaxoSmithKline Plc: Business Strategy

3.1.4.1 Product Level Strategy

3.1.5 SWOT Analysis of GlaxoSmithKline Plc

Strengths

Weaknesses

Opportunities

Threats

4. Current and Future Trends in Pharmaceutical Market

List of Exhibits

Notes

Company Information

List of Exhibits

Exhibit 2.1 Growth Drivers and Inhibitors for Global Pharmaceuticals Market

Exhibit 3.1 Key information of GlaxoSmithKline Plc

Exhibit 3.2 Contact Information GlaxoSmithKline Plc

Exhibit 3.3 GlaxoSmithKline Plc in Pharmaceuticals Manufacturing Value Chain

Exhibit 3.4 Revenue of GlaxoSmithKline Plc FY 2013- FY 2019 (in USD billion)

Exhibit 3.5 Revenue Growth of GlaxoSmithKline Plc FY 2014- FY 2019 (in %)

Exhibit 3.6 Division-Wise Revenue of GlaxoSmithKline Plc in FY 2018 (in USD billion)

Exhibit 3.7 Pharmaceuticals Division Revenue of GlaxoSmithKline FY 2013- FY 2018 (in USD billion)

Exhibit 3.8 Vaccines Division Revenue of GlaxoSmithKline FY 2013- FY 2018 (in USD billion)

Exhibit 3.9 Consumer Healthcare Division Revenue of GlaxoSmithKline FY 2013- FY 2018 (in USD billion)

Exhibit 3.10 Geography-Wise Revenue of GlaxoSmithKline in FY 2018 (in USD billion)

Exhibit 3.11 Therapy Area-Wise Revenue of GlaxoSmithKline in FY 2018 (in USD billion)
Exhibit 3.12 Therapy and Geography Area-Wise Revenue of GlaxoSmithKline FY 2018 (in USD billion)
Exhibit 3.13 SWOT Analysis of GlaxoSmithKline Plc

GlaxoSmithKline Plc

Single User License (PDF)

- This license allows for use of a publication by one person.
- This person may print out a single copy of the publication.
- This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- This person cannot share the publication (or any information contained therein) with any other person or persons.
- Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
- Customers who infringe these license terms are liable for a Enterprise license fee.

Site License (PDF)*

- This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
- These users may print out a single copy of the publication.
- These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
- Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
- Customers who infringe these license terms are liable for a Enterprise license fee.

Enterprise License (PDF)*

- This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
- Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
- These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

About Us



Intelligence Rediscovered

NAVADHI is a market research company that helps global firms differentiate themselves, break market entry barriers, track their investments, develop business strategies and plan for future by providing actionable market research intelligence that helps them succeed.

Information

- [About Us](#)
- [Publications](#)
- [FAQs](#)
- [Privacy Policy](#)
- [Terms & Conditions](#)
- [Careers](#)
- [Press Releases](#)
- [Contact](#)

Contact Info

C-3/81, 3rd Floor, Vibhuti Khand, Gomti Nagar, Lucknow, Uttar Pradesh, India - 226010

Mon - Sat: 9:00 - 18:00

Source URL: <https://www.navadhi.com/publications/glaxosmithkline-plc-company-snapshot-swot-analysis>

Links

[1] <https://www.navadhi.com/countries/global>

[2] <https://www.navadhi.com/publications/global-pharmaceuticals-industry-analysis-and-trends-2023>